Your browser doesn't support javascript.
loading
Applicability of selected Brighton Collaboration case definitions in low-resource settings: A prospective hospital-based active surveillance in Addis Ababa, Ethiopia.
Sintayehu, Kassech; Shaum, Anna; Bonger, Zelalem Tazu; Dagnachew Zeleke, Eden; Mamo, Biniyam Tedla; Anito, Abenezer Abraham; Bekele, Dawit; Longley, Ashley T; Gashaw, Habtamu; Alemu, Asnakech; Degefaw, Desalegne; Wang, Shu-Hua; Huang, Wan-Ting.
Affiliation
  • Sintayehu K; Ohio State Global One Health, Addis Ababa, Ethiopia. Electronic address: sintayehumolla.1@osu.edu.
  • Shaum A; Global Immunization Division, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
  • Bonger ZT; Ohio State Global One Health, Addis Ababa, Ethiopia.
  • Dagnachew Zeleke E; Ohio State Global One Health, Addis Ababa, Ethiopia.
  • Mamo BT; Ohio State Global One Health, Addis Ababa, Ethiopia.
  • Anito AA; Ohio State Global One Health, Addis Ababa, Ethiopia.
  • Bekele D; Ohio State Global One Health, Addis Ababa, Ethiopia.
  • Longley AT; Global Immunization Division, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
  • Gashaw H; Ethiopian Food and Drug Authority (EFDA), Addis Ababa, Ethiopia.
  • Alemu A; Ethiopian Food and Drug Authority (EFDA), Addis Ababa, Ethiopia.
  • Degefaw D; Ohio State Global One Health, Addis Ababa, Ethiopia.
  • Wang SH; Ohio State University Global One Health Initiative (OSU GOHi), Columbus, OH, USA.
  • Huang WT; Brighton Collaboration, Task Force for Global Health, Decatur, GA, USA; Global Health Program, College of Public Health, National Taiwan University, Taipei, Taiwan; National Taiwan University Children's Hospital, Taipei, Taiwan.
Vaccine ; 42(24): 126079, 2024 Oct 24.
Article in En | MEDLINE | ID: mdl-38909000
ABSTRACT

INTRODUCTION:

Standardizing case definitions for priority vaccine safety conditions facilitates uniform evaluation and consolidation of data obtained from different settings. The Brighton Collaboration case definitions (BCCD) were created to support this harmonization and enable classification from level 1 (most certain) to level 5 (not a case) of certainty. Assessing the performance of BCCD in practice is critical, particularly in resource-limited settings, where many new vaccines may be introduced without prior monitoring in high-income countries. We assessed the performance of BCCD in Addis Ababa, Ethiopia, as applicable to COVID-19 and other vaccines.

METHODS:

Active surveillance was conducted at Tikur Anbessa Specialized Hospital, the largest referral hospital in Ethiopia. During June 1, 2022-May 31, 2023, three trained physicians prospectively identified patients eligible for COVID-19 vaccination (regardless of vaccine receipt) who presented with one or more of eleven pre-specified adverse events of special interest (AESI) from the emergency department and inpatient wards. Standardized data collection forms were used to capture patient information and assign level of certainty (LOC), regardless of vaccination status for COVID-19. We conducted descriptive analysis to characterize cases and the LOCs reached for each AESI.

RESULTS:

We detected 203 AESI cases. The most detected conditions were thrombosis and thromboembolism (n = 100, 49 %) and generalized convulsions (n = 38, 19 %). Ninety-six percent of the cases were confirmed at levels 1-3 (n = 187) or level 5 (n = 9) LOC. Non-classifiable (level 4) cases were observed for pericarditis (n = 2), encephalitis (n = 2), myelitis (n = 2), and generalized convulsion (n = 1).

CONCLUSION:

The BCCD were successfully applied in > 95 % of cases in a large referral hospital in Ethiopia, with generalized convulsion, pericarditis, and encephalomyelitis as the exceptions. We recommend further evaluation in other low-resource settings, particularly in rural or non-referral hospitals, to gain additional insights into performance of these definitions for revision or adaptation, as needed.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Country/Region as subject: Africa Language: En Journal: Vaccine Year: 2024 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Country/Region as subject: Africa Language: En Journal: Vaccine Year: 2024 Document type: Article Country of publication: